Discriminating deadly from harmless types of prostate cancer combining MR metabolomics and transcriptomics
- Prosjektnummer
- 46051300
- Ansvarlig person
- Ingrid Gribbestad
- Institusjon
- NTNU, ISB
- Prosjektkategori
- Flerårig prosjekt 2011
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis
Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.
PLoS One 2013;8(4):e62375. Epub 2013 apr 23
PMID: 23626811
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.
NMR Biomed 2013 May;26(5):600-6. Epub 2012 des 27
PMID: 23280546
Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples.
Clin Cancer Res 2012 Jun;18(12):3261-9. Epub 2012 apr 17
PMID: 22510345
Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
Invest Radiol 2012 Nov;47(11):624-33.
PMID: 23011187
A new method to provide a fresh frozen prostate slice suitable for gene expression study and MR spectroscopy.
Prostate 2011 Apr;71(5):461-9. Epub 2010 sep 21
PMID: 20860008
HR MAS MR spectroscopy in metabolic characterization of cancer.
Curr Top Med Chem 2011;11(1):2-26.
PMID: 20809888
Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness
ISMRM annual meeting 2013
Citrat og Spermin som markører for aggressiv prostatakreft.
Vitenskapelige forhandlinger / De norske kirurgiske foreninger 2012
Metabolic changes in citrate and spermine concentrations can predict prostate cancer aggressiveness.
ESMRMB; 2012-10-04 - 2012-10-06
Metabolic changes in citrate and spermine concentrations can predict prostate cancer agressiveness.
ESUR; 2012-10-25 - 2012-10-27
Metabolic changes in indolent and aggressive prostate cancer - correlations with the Gleason grading system.
Regionale forskningskonferanse; 2012-06-05 - 2012-06-06
Metabolic changes in indolent and aggressive prostate cancer- correlations with the Gleason grading system.
Metabomeeting; 2012-09-25 - 2012-09-27
Metabolomics changes in citrate and spermine concentrations can predict prostate cancer aggressiveness.
EMUC; 2012-11-16 - 2012-11-18
Spermine and citrate as MR biomarkers for predicting prostate cancer aggressiveness.
Personalized cancer care; 2012-09-07 - 2012-09-09
Citrate as a biomarker in discriminating aggressive from indolent form of prostate cancer by MR metabolomics-correlation with th
National PHD Conference in Medical Imaging; 2012-11-28 - 2012-11-29
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer – Investigation of correlation with Gleason score
20th Meeting of the EAU section of Urological Research (ESUR); 2012-10-25 - 2012-10-27
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer – Investigation of correlation with Gleason score
Regionale forskningskonferansen; 2012-06-05 - 2012-06-06
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer – Investigation of correlation with Gleason score
EMUC 2012; 2012-11-16 - 2012-11-18
Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer. Investigation of a correlation with Gleason scor
Instituttseminar ISB; 2012-10-19 - 2012-10-19
Quantitative 1H HR-MAS using LC Model shows glutamate, choline, glycerophosphocholine, and glucose as biomarkers of prostate can
ISMRM 2012; 2012-05-05 - 2012-05-11
FRESH PROSTATE TISSUE PROCUREMENT SUITABLE FOR INTEGRATIVE GENOMIC AND METABOLIC PROFILING
EUROPEAN UROLOGY SUPPLEMENTS Volume: 10 Issue: 2 Pages: 115-116
Correlation Between In Vivo 1H MRS and Ex Vivo 1H HR MAS in Spatially Matched Regions in Prostate Cancer Patients
ISMRM annual meeting; 2011-05-07 - 2011-05-13
Spatially matched in vivo and ex vivo MR molecular profiling of prostate cancer.
ESMRMB annual scientific meeting; 2011-10-06 - 2011-10-08
MR Imaging and Spectroscopy in Prostate and Colon Cancer Diagnostics
- Disputert:
- september 2012
- Hovedveileder:
- Ingrid Gribbestad
- Elise Sandsmark Prosjektdeltaker
- Kirsten Margrete Selnæs Postdoktorstipendiat
- Tone Frost Bathen Forskningsgruppeleder
- May-Britt Tessem Forsker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU